跳至主要内容
临床试验/NCT04191551
NCT04191551招募中不适用

The GAstric Precancerous Conditions Study

Stanford University1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2018年7月30日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
600
试验地点
1
主要终点
Histologic Progression or Regression Assessed by OLGA Score

研究概览

简要总结

Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer.

The Gastric Precancerous Conditions Study (GAPS) is an observational study of patients at elevated risk for gastric cancer. Investigators seek to recruit patients from endoscopy unit of Stanford Health Care, a large academic network of hospitals and clinics serving Northern California. Investigators will recruit patients who are both symptomatic (e.g. dyspepsia) and asymptomatic (e.g. referred for screening), and individuals both with known precursor lesions (such as intestinal metaplasia) or at high risk for carrying precursor lesions. A component of the study is long-term follow-up of individuals with gastric precursors. This is to understand their risk factors for histologic progression and regression. During both index and subsequent endoscopies, the study team will collect biospecimens (e.g. blood, saliva, gastric tissue).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
35 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects between the ages of 35 and 84, who are undergoing outpatient endoscopy for the following indications are eligible: abdominal pain, dyspepsia, iron deficiency anemia, Helicobacter assessment, surveillance of suspected or known intestinal metaplasia, evaluation for family history of gastric cancer

排除标准

  • Cannot give consent
  • Have history of gastric surgery
  • Have history of solid tumor or bone marrow transplant
  • Platelet Count < 70 or international normalized ratio > 1.5

结局指标

主要结局

Histologic Progression or Regression Assessed by OLGA Score

时间窗: at least 24 months after enrollment

Histologic progression or regression will be evaluated using the Operative Link on Gastritis Assessment (OLGA) score. This score stages the severity of atrophic gastritis based on histological findings.

Histologic Progression or Regression Assessed by OLGIM Score

时间窗: at least 24 months after enrollment

Histologic progression or regression will be assessed using the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) score. This score stages the extent of intestinal metaplasia.

Development of Dysplasia

时间窗: at least 24 months after enrollment

The presence or absence of dysplasia will be assessed as an indicator of histologic progression.

Development of Carcinoma

时间窗: at least 24 months after enrollment

The presence or absence of carcinoma will be assessed to evaluate disease progression.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验